Andreas F. Hottinger

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB).

M. Sanson, O. Chinot, A. Hottinger, 2016 .

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

Eilon D. Kirson, Yoram Palti, Steven A. Toms, 2017 .

Neurological outcome of long-term glioblastoma survivors

Lauren E. Abrey, L. Deangelis, A. Hottinger, 2009, Journal of Neuro-Oncology.